MAXIS Global Benefits Network in August 2016 launched the MAXIS Global Risk Solution, a global program management solution offering centralized multinational companies with large global footprints a single-employer, non-profit-sharing arrangement. Key advantages include better terms and conditions; economies of scale; greater predictability of premiums; a global financial view; and a single point of contact for underwriting. Eligible coverages include group death; survivor income; group disability benefits; as well as

In September 2016, Zurich appointed Jack Howell as regional chief executive officer for Asia Pacific, based in Hong Kong and reporting directly to Mario Greco, group chief executive officer. In April 2015, Generali, then still led by Greco, had appointed Howell as regional chief executive officer for Asia. Jack Howell, 46, a U.S. citizen, holds a B.S. in Quantitative Economics from Tufts University and an MBA from the University

AXA in July 2016 announced the appointment of Matthieu André as CEO of AXA Global Life & Savings, reporting to Paul Evans who is in charge of AXA’s life, savings, protection and health activities on a global basis. Matthieu André joined AXA in 1995 as a financial controller after a spell as an auditor and consultant with Ernst & Young. His career path included positions as VP, Corporate Finance

The emergence of new, more expensive, cancer drug therapies that help the immune system attack tumors is expected to increase cancer drug spending to over $150 billion by 2020 according to a global oncology report released by IMS Health Holdings. This represents an annual global growth rate for oncology drug spending of 7.5% to 10.5% through 2020, up from last year’s IMS forecast of 6% to 8% growth. The